146 Biologics in the treatment of relapsing polychondritis

RELAPSING POLYCHONDRITIS Biologics in Relapsing Polychondritis: A Literature Review

Background: There is no standardized therapeutic protocol for relapsing polychondritis (RP). Emergence of biologics holds much hope in the management of this connective tissue disease. Objectives: To evaluate the efficacy and safety of biologics in patients with active RP. Methods: A systematic review of the literature using PubMed was performed through December 2010. MeSH terms and keywords we...

Treatment of relapsing polychondritis with tocilizumab.

Relapsing polychondritis.

Relapsing polychondritis, an uncommon, chronic, multisystem disorder characterized by recurrent episodes of inflammation of cartilaginous tissues, can be life-threatening, debilitating, and difficult to diagnose. This review is based on the authors' experience with 36 patients with relapsing polychondritis who were followed from 1980 to 1997, 30 patients located elsewhere who completed a detail...

Successful treatment of relapsing polychondritis with infliximab.

Relapsing polychondritis (RP) is a rare and potentially fatal autoimmune disease in which an inappropriate immune response destroys the cartilage of the ears, larynx and nose. Many therapeutic approaches have been reported. We describe the results obtained with infliximab in a patient with RP unresponsive to conventional therapy. This therapy could be a new weapon to treat refractory RP.

Relapsing Polychondritis

Relapsing polychondritis (RP) is a rare systemic disease characterized by recurrent, widespread chondritis of the auricular, nasal, and tracheal cartilages. Additional clinical features include audiovestibular dysfunction, ocular inflammation, vasculitis, myocarditis, and nonerosive arthritis. Although the cause remains unknown, the etiology is suspected to be autoimmune. We describe a case of ...